CBiophan expands intellectual property

Biophan Technologies (West Henrietta, New York), a developer of next-generation medical technology, reported further expansion of its intellectual property portfolio in recent weeks with 13 new applications filed — resulting in 10% growth — to a total of 140 U.S. issued or pending patents, plus international patents.

The new applications cover manufacturing the high-voltage leads used with implantable cardioverter defibrillators, when used in an MRI environment; various nanomagnetic materials, design details of conductive leads and the use of nanomagnetic material to shield them from MRI-related energy; and patent applications licensed recently from Aachen Resonance for the visualization of stents.

Calypte not in compliance with Amex

Calypte Biomedical (Pleasanton, California) reported that it received a letter from the American Stock Exchange (Amex) on June 22 notifying the company that it is not in compliance with certain of the Amex's continued listing standards set forth in the Amex's company guide.

Specifically, the Amex noted that the company is not in compliance with Section 1003(a)(i), with shareholders' equity of less than $2 million and losses from continuing operations and/or net losses in two out of its three most recent fiscal years; Section 1003(a)(ii), with shareholders' equity of less than $4 million and losses from continuing operations and/or net losses in three out of its four most recent fiscal years; and Section 1003(a)(iii), with shareholders' equity of less than $6 million and losses from continuing operations and/or net losses in its five most recent fiscal years.

In order to maintain listing of its common stock on the Amex, the company must submit a plan by July 22 advising the Amex of the action it has taken, or will take, to bring it into compliance with the continued listing standards of the sections involved within a maximum of 18 months of receipt of the notification letter.

Ultrasonix launches Sonix RP

Ultrasonix Medical Corp. of Canada (Burnaby, British Columbia) has launched Sonix RP — which the company said is the "first fully functional" ultrasound research package for investigational purposes, intended for research, academic and scientific institutions. The company said the Sonix RP provides "the perfect balance of performance and affordability."

The Sonix RP was recently showcased at 2005 American Institute of Ultrasound Medicine meeting in Orlando, Florida.

Sonix RP is equipped with an investigational research package that includes pre-beam forming real-time acquisition software, RF mode and SDK (Software Development Kit) for client applications.

No Comments